The latter can be concluded from meta-analyses of cardiovascular outcomes trials examining SGLT-2 Is and GLP-1 RAs, which found significant effects on all endpoints, composite or individual, which have been explored in the present analysis, with the exception of stroke in trials employing SGLT-2 inhibitors21–24. The gene discussed is GLP1R; the disease is Stroke.